130256-46-1

Upstream product

• 50409-13-7 2,5,11-trioxatricyclo[4.3.1.14,8 ] undecan-3-one 
• 131245-85-7 (1S,3R,5S)-5-Benzyloxy-cyclohexane-1,3-diol 
• 95205-55-3 (1S,5R,7R)-3-Benzyloxymethyl-2,4-dioxa-bicyclo[3.3.1]nonan-7-ol 
• 130256-36-9 Acetic acid (1R,3S,5R)-3-benzyloxy-5-hydroxy-cyclohexyl ester 
• 84029-18-5 (1RS,3RS,6SR)-3-(benzyloxy)-7-oxabicyclo[4.1.0]heptane 
• 84049-33-2 (1SR,3RS,6RS)-3-(benzyloxy)-7-oxabicyclo[4.1.0]heptane 
• 135182-44-4 Acetic acid (1R,2R,5S)-5-benzyloxy-2-hydroxy-cyclohexyl ester 
• 131245-94-8 (S)-5-benzyloxy-2-cyclohexen-1-one 
• 130256-36-9 (1S,3S,5R)-1-acetoxy-5-benzyloxy-3-cyclohexanol 
• 130256-34-7 meso-1,3-cis,3,5-cis-1,3-diacetoxy-5-benzyloxycyclohexane 
• 130256-33-6 (1R,5S,7R)-7-Benzyloxy-3-benzyloxymethyl-2,4-dioxa-bicyclo[3.3.1]nonane 
• 130323-27-2 (1S,5R,7R)-3-Hydroxymethyl-2,4-dioxa-bicyclo[3.3.1]nonan-7-ol 
• 50409-12-6 cis,cis-1,3,5-trihydroxycyclohexane 

Downstream Products

• 140363-96-8 trans-(+/-)-5-Benzyloxy-2,3-epoxycyclohexanol 
• 140363-95-7 (3S,5S)-3-benzoyloxy-5-benzyloxy-1-cyclohexene 
• 131245-95-9 (3R,5S)-3-acetoxy-5-benzyloxy-1-cyclohexene 
• 140363-99-1 (2R,4R)-dimethyl 2-acetoxy-4-benzyloxyhexanedioate 
• 140364-00-7 (2R,4R)-dimethyl 4-benzyloxy-2-hydroxyhexanedioate 
• 140363-95-7 (3R,5S)-3-benzoyloxy-5-benzyloxy-1-cyclohexene 
• 140460-29-3 (4R,6R)-4-benzyloxy-6-methoxycarbonyltetrahydro-2-pyranone 
• 140460-25-9 cis-1,3-dibenzyloxycyclohexane 
• 140363-97-9 (1R,2S,3R,5R)-1,2,3-triacetoxy-5-benzyloxycyclohexane 
• 140363-98-0 (1R,2S,3R,5R)-1,2,3-triacetoxycyclohexan-5-ol 
• 140363-96-8 (+)-(1S,2R,4R,6R)-4-Benzyloxy-1,6-epoxycyclohexan-2-ol 
• 137767-18-1 (3R,5S)-5-benzyloxy-1-cyclohexen-3-ol 
• 131245-96-0 (2S,4R)-dimethyl 2-acetoxy-4-benzyloxyhexanedioate 
• 131245-97-1 (2S,4R)-dimethyl 4-benzyloxy-2-hydroxyhexanedioate 

Relevant academic research and scientific papers

Synthesis and inhibitory properties of (1R,2R,4R,6R)-6-O-(2-hydroxyethyl)cyclohexane-1,2,4,6-tetraol derivatives: Mechanistic probes for the inositol monophosphatase reaction

The phosphate derivatives 2, 3 and 4 of 6-O-(2-hydroxyethyl)cyclohexane-1,2,4,6-tetraol have been designed to inhibit inositol monophosphatase, the putative target for lithium therapy, by interacting simultaneously with both cofactor metal ions at the active site of the enzyme. The compounds have been synthesised, via the known key common intermediate cyclohexene oxide, from cyclohexane-1,4-diol in moderate yield, and have been tested for activity in standard enzyme assays. Each compound serves as a competitive inhibitor and displays the expected inhibitory properties. Indeed, compound 4 and the cyclic phosphate 3 of 6-O-(2-hydroxyethyl)cyclohexane-1,2,4,6-tetraol are, respectively, the most potent examples of a primary alkyl phosphate inhibitor and a phosphate monoanion inhibitor yet reported for the enzyme. The stereochemistry of the most potent inhibitor, (1R,2R,4R,6R)-2 as deduced from the X-ray crystal structure of a synthetic precursor, provides useful mechanistic insight into the action of the enzyme and the mode of inhibitor binding.

Enantioselective synthesis of (1S,3S,5R)-1-acetoxy-5-benzyl-oxycyclohexan-3-ol and its application to the synthesis of compactin lactone moiety and quinic acid

Porcine liver esterase (PLE)-catalyzed asymmetric hydrolysis of meso-1,3-cis,3,5-cis-1,3-diacetoxy-5-benzyloxycyclohexane 1 afforded (1S,3S,5R)-2 of 87% e.e. Starting from this compound, compactin lactone moiety 17A and its C-6 diastereomer 17B were diast

ENANTIOTOPOSELECTIVE PLE-CATALYZED HYDROLYSIS OF CIS-5-SUBSTITUTED-1,3-DIACYLOXYCYCLOHEXANES. PREPARATION OF SOME USEFUL CHIRAL BUILDING BLOCKS

PLE-catalyzed hydrolysis of prochiral cis-5-benzyloxymethyl-1,3-diacetoxycyclohexane and cis-5-benzyloxy-1,3-diacetoxycyclohexane proceeds with high enantiotoposelectivity.The preparation of some useful chiral building blocks is described.